IL1RL2 and neoplasm: We have utilised the CT26 mouse colorectal tumour model to demonstrate that inhibiting IL-36R signalling by administration of IL-36Ra, or by CRISPR Cas9-mediated IL-36R knockout in tumour cells, results in a reduced tumour burden in mice with a reduction in tumour cell proliferation, indicating that targeting of the IL-36R in CRC may have potential therapeutic benefits.